Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Filgrastim Biosimilars Market Report 2024

Filgrastim Biosimilars Global Market Report 2025 – By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing organization), By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

Filgrastim Biosimilars Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Filgrastim Biosimilars Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Filgrastim Biosimilars Market Definition

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how IT helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

The two main types of manufacturing for the filgrastim biosimilar market are in-house manufacturing and contract manufacturing organization. A contract manufacturing organization, also known as a contract development and manufacturing organization, is a corporation that provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production. The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

Filgrastim Biosimilars Market Segmentation

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Filgrastim Biosimilars Market Size and growth rate 2025 to 2029: Graph

Filgrastim Biosimilars Market Size 2025 And Growth Rate

The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $0.92 billion in 2024 to $0.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure.

Filgrastim Biosimilars Market Growth Forecast

The filgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population, increase in healthcare access. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies.

Book your 30 minutes free consultation with our research experts

Contact Us

Filgrastim Biosimilars Market Driver: Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market

The increasing prevalence of neutropenia is expected to propel the growth of the filgrastim biosimilar market going forward. Neutropenia refers to a condition where the body does not have enough neutrophils, which are an important type of white blood cell that fights infections. Filgrastim biosimilars work by stimulating the production of neutrophils in the bone marrow, which increases the neutrophil count and helps fight infections. For instance, in August 2022, according to the National Center for Biotechnology Information, a US-based database for biomedical literature, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Thus, the increasing prevalence of neutropenia is driving the growth of the filgrastim biosimilar market.

Filgrastim Biosimilars Market Driver: Government-Led Biosimilar Initiatives Fuel Growth In The Filgrastim Biosimilar Market

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilar markets market over the coming years. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government's initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the filgrastim biosimilar markets market.

Global Filgrastim Biosimilars Market Major Players

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

Global Filgrastim Biosimilars Market Trend: Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant DNA Technology

Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States indicated for the treatment and prevention of febrile neutropenia. It promotes the expansion and specialization of neutrophils originating from dedicated precursor cells, triggers their maturation, and improves the viability and efficiency of fully developed neutrophils, leading to dosage-dependent rises in neutrophil counts. The launch of Fylnetra contributes to the next wave of affordable medicines and drives access across patients, providers, and payors.

Global Filgrastim Biosimilars Market Trend: Amneal Pharmaceuticals And Kashiv Biosciences Revolutionize Cancer Care With Releuko (Filgrastim-Ayow), A Breakthrough Biosimilar For Febrile Neutropenia

Major companies operating in the filgrastim biosimilar market are developing innovative products such as Releuko (filgrastim-ayow) to better serve patients. Releuko (filgrastim-ayow) is a biosimilar referencing Neupogen (filgrastim) and is indicated for the treatment and prevention of febrile neutropenia in patients with cancer undergoing chemotherapy. For instance, in November 2022, Amneal Pharmaceuticals, a US-based pharmaceutical company, and Kashiv Biosciences, a US-based biosciences company launched Releuko (filgrastim-ayow) in the US market. It is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or peg filgrastim products. The approval of Releuko marks the first biosimilar for Amneal, with two more decisions expected by the end of the year.

Filgrastim Biosimilars Market Merger And Acquisition: Biocon Biologics' Transformative Acquisition Of Viatris Inc

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc. for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc. is a US-based pharmaceutical company that has developed a biosimilar of peg filgrastim.

Regional Outlook For The Global Filgrastim Biosimilars Market

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

What Defines the Filgrastim Biosimilars Market?

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Filgrastim Biosimilars Industry?

The filgrastim biosimilar markets market research report is one of a series of new reports from The Business Research Company that provides filgrastim biosimilar markets market statistics, including filgrastim biosimilar markets industry global market size, regional shares, competitors with a filgrastim biosimilar markets market share, detailed filgrastim biosimilar markets market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilar markets industry. This filgrastim biosimilar markets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Filgrastim Biosimilars Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $0.98 billion
Revenue Forecast In 2034 $1.21 billion
Growth Rate CAGR of 5.4% from 2024 to 2033
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Filgrastim Biosimilars Market Characteristics

    3. Filgrastim Biosimilars Market Trends And Strategies

    4. Filgrastim Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

    5. Global Filgrastim Biosimilars Growth Analysis And Strategic Analysis Framework

    5.1. Global Filgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Filgrastim Biosimilars Market Growth Rate Analysis

    5.4. Global Filgrastim Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Filgrastim Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Filgrastim Biosimilars Total Addressable Market (TAM)

    6. Filgrastim Biosimilars Market Segmentation

    6.1. Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    In-House Manufacturing

    Contract Manufacturing Organization

    6.2. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oncology

    Chronic And Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Other Applications

    6.3. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    6.4. Global Filgrastim Biosimilars Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Proprietary In-House Manufacturing Facilities

    Company-Owned Production Plants

    Vertically Integrated Manufacturing

    6.5. Global Filgrastim Biosimilars Market, Sub-Segmentation Of Contract Manufacturing Organization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Full-Service Contract Manufacturing

    Fill and Finish Services

    API (Active Pharmaceutical Ingredient) Manufacturing

    Specialized Biosimilar Manufacturing Services

    7. Filgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Filgrastim Biosimilars Market

    8.1. Asia-Pacific Filgrastim Biosimilars Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Filgrastim Biosimilars Market

    9.1. China Filgrastim Biosimilars Market Overview

    9.2. China Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Filgrastim Biosimilars Market

    10.1. India Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Filgrastim Biosimilars Market

    11.1. Japan Filgrastim Biosimilars Market Overview

    11.2. Japan Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Filgrastim Biosimilars Market

    12.1. Australia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Filgrastim Biosimilars Market

    13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Filgrastim Biosimilars Market

    14.1. South Korea Filgrastim Biosimilars Market Overview

    14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Filgrastim Biosimilars Market

    15.1. Western Europe Filgrastim Biosimilars Market Overview

    15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Filgrastim Biosimilars Market

    16.1. UK Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Filgrastim Biosimilars Market

    17.1. Germany Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Filgrastim Biosimilars Market

    18.1. France Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Filgrastim Biosimilars Market

    19.1. Italy Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Filgrastim Biosimilars Market

    20.1. Spain Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Filgrastim Biosimilars Market

    21.1. Eastern Europe Filgrastim Biosimilars Market Overview

    21.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Filgrastim Biosimilars Market

    22.1. Russia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Filgrastim Biosimilars Market

    23.1. North America Filgrastim Biosimilars Market Overview

    23.2. North America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Filgrastim Biosimilars Market

    24.1. USA Filgrastim Biosimilars Market Overview

    24.2. USA Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Filgrastim Biosimilars Market

    25.1. Canada Filgrastim Biosimilars Market Overview

    25.2. Canada Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Filgrastim Biosimilars Market

    26.1. South America Filgrastim Biosimilars Market Overview

    26.2. South America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Filgrastim Biosimilars Market

    27.1. Brazil Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Filgrastim Biosimilars Market

    28.1. Middle East Filgrastim Biosimilars Market Overview

    28.2. Middle East Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Filgrastim Biosimilars Market

    29.1. Africa Filgrastim Biosimilars Market Overview

    29.2. Africa Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

    30.1. Filgrastim Biosimilars Market Competitive Landscape

    30.2. Filgrastim Biosimilars Market Company Profiles

    30.2.1. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Intas Biopharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Dr. Reddy's Laboratories Overview, Products and Services, Strategy and Financial Analysis

    31. Filgrastim Biosimilars Market Other Major And Innovative Companies

    31.1. Pfizer

    31.2. Cadila Healthcare Ltd

    31.3. Reliance Life Science Pvt. Ltd

    31.4. Gennova Biopharmaceuticals (Emcure)

    31.5. Sandoz Pty Ltd

    31.6. Mylan

    31.7. Lupin Limited

    31.8. Coherus Biosciences Inc.

    31.9. North China Pharmaceutical Corporation

    31.10. Tonghua Dongbaoare

    31.11. Beijing SL Pharmaceutical

    31.12. Fuji Pharma

    31.13. Adello Biologics

    31.14. Apobiologix (Apotex)

    31.15. Hospira

    32. Global Filgrastim Biosimilars Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

    34. Recent Developments In The Filgrastim Biosimilars Market

    35. Filgrastim Biosimilars Market High Potential Countries, Segments and Strategies

    35.1 Filgrastim Biosimilars Market In 2029 - Countries Offering Most New Opportunities

    35.2 Filgrastim Biosimilars Market In 2029 - Segments Offering Most New Opportunities

    35.3 Filgrastim Biosimilars Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Filgrastim Biosimilars Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Filgrastim Biosimilars Market, Sub-Segmentation Of Contract Manufacturing Organization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Teva Pharmaceutical Industries Ltd Financial Performance
  • Table 77: Novartis International AG Financial Performance
  • Table 78: Biocon Limited Financial Performance
  • Table 79: Intas Biopharmaceuticals Financial Performance
  • Table 80: Dr. Reddy's Laboratories Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Filgrastim Biosimilars Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Filgrastim Biosimilars Market, Sub-Segmentation Of Contract Manufacturing Organization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Teva Pharmaceutical Industries Ltd Financial Performance
  • Figure 77: Novartis International AG Financial Performance
  • Figure 78: Biocon Limited Financial Performance
  • Figure 79: Intas Biopharmaceuticals Financial Performance
  • Figure 80: Dr. Reddy's Laboratories Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Read More

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Read More

The Microbiome Market Share, Market Size, And Growth Rate 2022

Read More

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the pegfilgrastim biosimilars market market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the oncology drugs market research report 2022 with industry size, share, segments and market growth

Read More

Neutropenia Biologic Drug Treatment Global Market Report 2025 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2025 – By Type (Pegfilgrastim, Lenograstim, Filgrastim, Other Types), By Product (Tablet, Capsule, Other Products), By Application (Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pegfilgrastim Biosimilars Global Market Report 2025 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Biosimilars Global Market Report 2025 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Oncology Biosimilars Global Market Report 2025 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Trastuzumab Biosimilars Global Market Report 2025 – By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Rituximab Biosimilars Global Market Report 2025 – By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), By Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Mail Order) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the Filgrastim Biosimilars market?

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections. For further insights on the Filgrastim Biosimilars market, request a sample here

How will the Filgrastim Biosimilars market drivers and restraints affect the market dynamics? What forces will shape the Filgrastim Biosimilars industry going forward?

The Filgrastim Biosimilars market major growth driver - Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market. For further insights on the Filgrastim Biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the Filgrastim Biosimilars market?

The Filgrastim Biosimilars market size has grown strongly in recent years. The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $0.92 billion in 2024 to $0.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure. The filgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population, increase in healthcare access. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies. For further insights on the Filgrastim Biosimilars market, request a sample here

How is the Filgrastim Biosimilars market segmented?

The filgrastim biosimilars market covered in this report is segmented –
1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services For further insights on the Filgrastim Biosimilars market, request a sample here

Which region has the largest share of the Filgrastim Biosimilars market? What are the other regions covered in the report?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Filgrastim Biosimilars market, request a sample here.

Who are the major players in the Filgrastim Biosimilars market?

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios . For further insights on the Filgrastim Biosimilars market, request a sample here.

What are the key trends in the Filgrastim Biosimilars market?

Major trends in the Filgrastim Biosimilars market include Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant DNA Technology. For further insights on the Filgrastim Biosimilars market, request a sample here.

What are the major opportunities in the Filgrastim Biosimilars market? What are the strategies for the Filgrastim Biosimilars market?

For detailed insights on the major opportunities and strategies in the Filgrastim Biosimilars market, request a sample here.

How does the Filgrastim Biosimilars market relate to the overall economy and other similar markets?

For detailed insights on Filgrastim Biosimilars's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Filgrastim Biosimilars industry?

For detailed insights on the mergers and acquisitions in the Filgrastim Biosimilars industry, request a sample here.

What are the key dynamics influencing the Filgrastim Biosimilars market growth? SWOT analysis of the Filgrastim Biosimilars market.

For detailed insights on the key dynamics influencing the Filgrastim Biosimilars market growth and SWOT analysis of the Filgrastim Biosimilars industry, request a sample here.